Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/52—Two oxygen atoms
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
  • A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/30—Halogen atoms or nitro radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/34—One oxygen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Definitions

• Symmetrical and unsymmetrical 4,6-bis(aryloxy)-pyrimidine compounds which are useful as pesticidal agents are described in WO 94/02470.
• Symmetrical 4,6-bis(aryloxy)pyrimidine compounds are prepared in one step by reacting a 4,6-dihalopyrimidine compound with two molar equivalents of a phenol compound.
• unsymmetrical 4,6-bis(aryloxy) pyrimidine compounds are significantly more difficult to prepare because the aryloxy groups must be introduced by separate reactions.
• WO 94/02470 discloses that unsymmetrical 4,6-bis-(aryloxy)pyrimidine compounds are prepared by reacting a 4,6-dihalopyrimidine compound with one molar equivalent of a first phenol compound in the presence of a base and then reacting the resulting compound with a second phenol compound in the presence of a base.
• that process is not entirely satisfactory for the commercial manufacture of unsymmetrical 4,6-bis(aryloxy)pyrimidine compounds.
• 4,6-dichloropyrimidine scrambling of the aryloxy groups occurs, producing symmetrical compounds which are difficult to separate from the desired unsymmetrical product, as shown in Flow Diagram I.
• 4,6-difluoropyrimidine has been used.
• 4,6-difluoropyrimidine is prepared from 4,6-dichloropyrimidine by a halogen exchange reaction which requires the use of costly reagents and consumes a large amount of energy.
• the present invention provides an improved process for the preparation of an unsymmetrical 4,6-bis(aryloxy)-pyrimidine compound having the structural formula I wherein
• the process of this invention provides unsymmetrical 4,6-bis(aryloxy) pyrimidine compounds in higher yield than the art processes, overcomes the scrambling problem associated with the use of 4,6-dichloropyrimidine, uses less costly reagents than the 4,6-difluoropyrimidine art process, and avoids the isolation and multiple solvent requirements of the ammonium halide art process.
• the process of the present invention preferably comprises reacting a formula II 4-halo-6-(aryloxy)-pyrimidine compound as described above with at least about one molar equivalent of the amine as described above in the presence of a solvent selected from the group consisting of an aromatic hydrocarbon and a halogenated aromatic hydrocarbon and mixtures thereof preferably at a temperature of about 0 °C to 100 °C to form a formula III ammonium halide compound as described above, and reacting the formula III compound in situ with at least about one molar equivalent of a formula IV phenol compound as described above and at least about one molar equivalent of the base preferably at a temperature of about 0 °C to 100 °C to form the desired unsymmetrical 4,6-bis(aryloxy)pyrimidine compound of formula I.
• the reaction scheme is shown in Flow Diagram II.
• Aromatic hydrocarbons suitable for use in the process of the present invention include, but are not limited to, toluene, xylenes, benzene and the like and mixtures thereof with toluene being preferred.
• Halogenated aromatic hydrocarbons suitable for use include, but are not limited to, chlorobenzene, fluorobenzene, bromobenzene and the like and mixtures thereof.
• the amines that may be used in the process of the invention to prepare the ammonium halide compounds are alkyl amines, 5- to 6-membered saturated and 5- to 14-membered unsaturated heterocyclic amines optionally substituted with one to three C 1 -C 4 alkyl groups or C 1 -C 4 alkoxy groups.
• the preferred amines are C 1 -C 4 trialkylamines, 5- to 6-membered saturated heterocyclic amines, and 5- to 14-membered unsaturated heterocyclic amines wherein the heterocyclic ring system contains one to three nitrogen atoms and optionally include sulfur or oxygen in the ring system.
• the more preferred amines include trimethylamine, triethylamine, the saturated heterocyclic amines including, but not limited to, pyridines, picolines, pyrazines, pyridazines, triazines, quinolines, isoquinolines, imidazoles, benzothiazoles and benzimidazoles, optionally substituted with one to three C 1 -C 4 alkyl groups or C 1 -C 4 alkoxy groups, and unsaturated heterocyclic amines such as pyrrolidines, piperidines, piperazines, morpholines, thiazolidines and thiamorpholines.
• the saturated heterocyclic amines including, but not limited to, pyridines, picolines, pyrazines, pyridazines, triazines, quinolines, isoquinolines, imidazoles, benzothiazoles and benzimidazoles, optionally substituted with one to three C 1 -C 4 alkyl groups or
• Bases suitable for use in the process of the present invention include, but are not limited to, alkali metal carbonates such as sodium carbonate and potassium carbonate, alkaline earth metal carbonates such as calcium carbonate and magnesium carbonate, alkali metal hydrides such as sodium hydride and potassium hydride, alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, and alkaline earth metal hydroxides such as calcium hydroxide and magnesium hydroxide, with alkali metal carbonates being preferred.
• an alkyl group is suitably a straight chain or branched chain group containing up to 8 carbon atoms, for example up to 6 carbon atoms.
• an alkyl group contains up to 4 carbon atoms.
• An alkyl moiety which forms part of another group for example the alkyl of a haloalkyl group or each alkyl of an alkoxyalkyl group, suitably has up to 6 carbon atoms, preferably up to 4 carbon atoms.
• halogen is fluorine, chlorine, bromine or iodine.
• Haloalkyl and haloalkoxy are especially trifluoromethyl, pentafluoroethyl and trifluoromethoxy.
• the formula II compounds of the present invention may be prepared by reacting a 4,6-dihalopyrimidine compound of formula V wherein R 4 is as described hereinabove and X is Cl, Br or I with up to one molar equivalent of a phenol compound of formula VI wherein R, R 1 , R 2 and R 3 are as described hereinabove and a base in the presence of a solvent preferably at a temperature of about 0 °C to 100 °C.
• Bases suitable for use in the preparation of formula II compounds include, but are not limited to, alkali metal carbonates such as sodium carbonate and potassium carbonate, alkaline earth metal carbonates such as calcium carbonate and magnesium carbonate, alkali metal hydrides such as sodium hydride and potassium hydride, alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, and alkaline earth metal hydroxides such as calcium hydroxide and magnesium hydroxide.
• Solvents suitable for use in the preparation of formula II compounds include, but are not limited to, ethers such as diethyl ether, tetrahydrofuran and dioxane, carboxylic acid amides such as N,N-dimethylformamide and N,N-dimethylacetamide, halogenated hydrocarbons such as 1,2-dichloroethane, carbon tetrachloride, methylene chloride and chloroform, sulfoxides such as dimethyl sulfoxide, ketones such as acetone an N-methylpyrrolidone, aromatic hydrocarbons such as toluene, xylenes and benzene, halogenated aromatic hydrocarbons such as chlorobenzene, fluorobenzene and bromobenzene, and mixtures thereof, and mixtures with water.
• ethers such as diethyl ether, tetrahydrofuran and dioxane
• carboxylic acid amides such as N,N
• Preferred solvents for use in the preparation of formula II compounds include carboxylic acid amides, aromatic hydrocarbons, halogenated aromatic hydrocarbons, aromatic hydrocarbon/water mixtures, and halogenated aromatic hydrocarbon/water mixtures. It should be understood that when the solvent includes water, a base which is suitably stable in water should be used.
• the overall process used to prepare the desired formula I compound from a 4,6-dihalopyrimidine compound of formula V may be integrated when the solvent used to prepare the formula II compound is an aromatic hydrocarbon/water or a halogenated aromatic hydrocarbon/water mixture.
• the integration is achieved by removing the water from the solvent system after the formula II compound is formed. The water may be removed using standard procedures such as decanting.
• the resultant aromatic hydrocarbon or halogenated aromatic hydrocarbon solvent, which contains the formula II compound, may then be used directly in the next step of the process.
• Trimethylamine (35.5 g, 0.6 mol) is bubbled through a mixture of 4-chloro-6-[( ⁇ , ⁇ , ⁇ ,4-tetrafluoro- m -tolyl)-oxy]pyrimidine (58.5 g, 0.2 mol) in toluene (250 mL) at room temperature over 2.5 hours.
• the resultant reaction mixture is stirred for 18 hours, treated with potassium carbonate (27.6 g, 0.2 mol) and ⁇ , ⁇ , ⁇ -trifluoro-4-chloro- m -cresol (39.3 g, 0.2 mol), stirred for three hours, and diluted with water.
• the title product is prepared in 91.6% yield starting from 4-chloro-6-[(a,a,a,4-tetrafluoro- m -tolyl)oxy]pyrimidine.
• ⁇ , ⁇ , ⁇ -Trifluoro-4-chloro- m -cresol (1,118.9 g, 5.69 mol) is added to a mixture of trimethyl ⁇ 6-[( ⁇ , ⁇ , ⁇ ,4-tetrafluoro- m -tolyl)oxy] -4-pyrimidyl ⁇ ammonium chloride (1,962.0 g, 5.58 mol) and potassium carbonate (793.2 g, 5.74 mol) in N,N-dimethylformamide (8.5 L).
• the reaction mixture is stirred overnight at room temperature, cooled to 5 °C and slowly diluted with water (2.27 L). The resultant aqueous mixture is filtered to give a solid.
• the process of the present invention provides 4-[(4-chloro- ⁇ , ⁇ , ⁇ -trifluoro- m -tolyl)oxy]-6-[( ⁇ , ⁇ , ⁇ ,4-tetrafluoro- m -tolyl)oxy]pyrimidine in significantly higher yield starting from 4-chloro-6-[( ⁇ , ⁇ , ⁇ ,4-tetrafluoro- m -tolyl)oxy]pyrimidine than the art process (91.6% vs. 55.2%).
• Trimethylamine gas (127.6 g, 2.16 mol) is bubbled through a solution of all of the 4-chloro-6-[( ⁇ , ⁇ , ⁇ ,4-tetrafluoro-m-tolyl)oxy]pyrimidine obtained in step (a) in toluene (800 mL) over 2.5 hours.
• the resulting mixture is stirred for 18 hours, treated with potassium carbonate (99.8 g, 0.72 mol) and ⁇ , ⁇ , ⁇ -trifluoro-4-chloro- m -cresol (141.7 g, 0.72 mol) over 20 minutes, stirred at room temperature for 5 hours, diluted with water (800 mL), and stirred for 15 minutes.
• Example 3 the title product is prepared in 67% isolated yield starting from 4,6-dichloropyrimidine and ⁇ , ⁇ , ⁇ ,4-tetrafluoro- m -cresol.
• ⁇ , ⁇ , ⁇ ,4-Tetrafluoro- m -cresol (1,208.9 g, 6.71 mol) is slowly added to a mixture of 4,6-dichloropyrimidine (1,000.0 g, 6.71 mol) and potassium carbonate (967.5 g, 7.00 mol) in N,N-dimethylformamide (10 L).
• the reaction mixture is stirred overnight at room temperature, stirred at 45 °C for 2 hours, stirred at 71 °C for 2 hours, stirred overnight at room temperature and poured into water (20 L).
• the resultant aqueous mixture is extracted with methylene chloride.
• ⁇ , ⁇ , ⁇ -Trifluoro-4-chloro- m -cresol (1,118.9 g, 5.69 mol) is added to a mixture of trimethyl ⁇ 6-[( ⁇ , ⁇ , ⁇ ,4-tetrafluoro- m -tolyl)oxy]-4-pyrimidyl ⁇ ammonium chloride (1,962.0 g, 5.58 mol) and potassium carbonate (793.2 g, 5.74 mol) in N,N-dimethylformamide (8.5 L).
• the reaction mixture is stirred overnight at room temperature, cooled to 5 °C and slowly diluted with water (2.27 L). The resultant aqueous mixture is filtered to give a solid.
• Example 4 the art process provides the title product in 55% overall yield starting from 4,6-dichloropyrimidine and ⁇ , ⁇ , ⁇ ,4-tetrafluoro- m -cresol.
• the process of the present invention provides 4-[(4-chloro- ⁇ , ⁇ , ⁇ -trifluoro- m -tolyl)oxy]-6-[( ⁇ , ⁇ , ⁇ ,4-tetrafluoro -m -tolyl)oxy]pyrimidine in significantly higher yield starting from 4,6-dichloropyrimidine and ⁇ , ⁇ , ⁇ ,4-tetrafluoro- m -cresol than the art process (67% vs. 55%).
• Trimethylamine gas (127.6 g, 2.16 mol) is bubbled through a solution of all of the 4-chloro-6-[(4-chloro-a,a,a-trifluoro- m -tolyl)oxy]pyrimidine obtained in step (a) in toluene (800 mL) over 2.5 hours.
• the resulting mixture is stirred for 18 hours, treated with potassium carbonate (99.5 g, 0.72 mol) and ⁇ , ⁇ , ⁇ ,4-tetrafluoro- m -cresol (129.7 g, 0.72 mol) over 20 minutes, stirred at room temperature for 5 hours, diluted with water (800 mL), and stirred for 15 minutes.
• the title product is prepared in 70% yield starting from 4,6-dichloropyrimidine and ⁇ , ⁇ , ⁇ -trifluoro-4-chloro- m -cresol.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Dentistry (AREA)
• Wood Science & Technology (AREA)
• Plant Pathology (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Agronomy & Crop Science (AREA)
• General Health & Medical Sciences (AREA)
• Pest Control & Pesticides (AREA)
• Zoology (AREA)
• Environmental Sciences (AREA)
• Plural Heterocyclic Compounds (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=25457617

Family Applications (1)

Country Status (21)

Families Citing this family (4)

Family Cites Families (8)

• 1997
  • 1997-09-05 US US08/929,293 patent/US5849910A/en not_active Expired - Fee Related
• 1998
  • 1998-08-26 TW TW087114030A patent/TW505638B/zh not_active IP Right Cessation
  • 1998-08-28 CZ CZ19982755A patent/CZ291587B6/cs not_active IP Right Cessation
  • 1998-08-31 IL IL12599798A patent/IL125997A/en not_active IP Right Cessation
  • 1998-08-31 JP JP10259098A patent/JPH11147879A/ja not_active Withdrawn
  • 1998-08-31 KR KR1019980035505A patent/KR100555053B1/ko not_active IP Right Cessation
  • 1998-09-01 ES ES98306988T patent/ES2169480T3/es not_active Expired - Lifetime
  • 1998-09-01 DE DE69802636T patent/DE69802636T2/de not_active Expired - Fee Related
  • 1998-09-01 PT PT98306988T patent/PT902020E/pt unknown
  • 1998-09-01 EP EP98306988A patent/EP0902020B1/en not_active Expired - Lifetime
  • 1998-09-01 AT AT98306988T patent/ATE209636T1/de not_active IP Right Cessation
  • 1998-09-02 MX MXPA98007127A patent/MXPA98007127A/es not_active IP Right Cessation
  • 1998-09-02 AU AU83047/98A patent/AU735102B2/en not_active Ceased
  • 1998-09-02 ZA ZA9808032A patent/ZA988032B/xx unknown
  • 1998-09-02 SK SK1209-98A patent/SK285101B6/sk not_active IP Right Cessation
  • 1998-09-03 NZ NZ331701A patent/NZ331701A/xx unknown
  • 1998-09-03 CA CA002246588A patent/CA2246588A1/en not_active Abandoned
  • 1998-09-03 CN CNB981188737A patent/CN1139577C/zh not_active Expired - Fee Related
  • 1998-09-04 BR BR9803388A patent/BR9803388A/pt not_active Application Discontinuation
  • 1998-09-04 HU HU9802020A patent/HU226270B1/hu not_active IP Right Cessation
  • 1998-09-04 AR ARP980104421A patent/AR015431A3/es active IP Right Grant

Also Published As

Similar Documents

Legal Events